Cipla Lines Up A Slate Of US Launches For FY23
As COVID-19 Antibody Cocktail Now Available In India
Cipla signals meaningful US launch line-up in fiscal 2023, which analysts anticipate could include generic versions of Advair, Revlimid and Abraxane. Partnered peptide injectable filings also bolster pipeline opportunities.
You may also be interested in...
The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies.
Lannett continues to eye the potential launch of its partnered Advair generic next year, after the lucrative respiratory asset was accepted for filing by the FDA.
Coronavirus Update: Storage Boost For Pfizer/BioNTech, More Positive Data For Regeneron Antibody Cocktail
The approved fridge storage time for Pfizer and BioNTech's Comirnaty has been extended to a month, Regeneron's scores with low-dose REGEN-COV, an early win for GSK and CureVac's next-generation mRNA vaccine and more orders of the AstraZeneca vaccine benefits Oxford Biomedica's bank balance.